Philip Morris Hong Kong & Macau Announces U.S Food and Drug Administration Authorisation for the sale of IQOS in the United States
Philip Morris Hong Kong & Macau Announces U.S. Food and Drug Administration Authorisation for the sale of IQOS in the United States
Brett Cooper, General Manager of Philip Morris Hong Kong and Macau said, referring to the US FDA press release on 30 April, 2019 , “We welcome their decision that authorises IQOS for sale in the U.S. market and encourage everyone, including the Hong Kong Government, to read the US FDA’s statement and follow their example.”
He added that the order sets out clear commercialisation guidelines for the US, including marketing requirements, that maximise the opportunity for adults to switch from cigarettes, while minimising unintended use.
He said, “Given Hong Kong’s approach to pragmatic and evidence based regulation, this decision by the US FDA should be used as a key benchmark of what the Government should do in Hong Kong and that our new products can be regulated here in Hong Kong and made available only for adult smokers while preventing youth access.”
Attached please find a press statement issued by Philip Morris International in New York on 30, April, 2019. https://www.fda.gov/news-events/press-announcements/fda-permits-sale-iqos-tobacco-heating-system-through-premarket-tobacco-product-application-pathway
– End –